Short-term efficacy and safety of tavapadon for Parkinson's disease: An exploratory systematic review and meta-analysis of randomized clinical trials.
Théo Santana Campos, Pedro Sandes Pereira, Maria Eduarda Pires Marques et al.
✦ AI-curated · Sources linked
In 30 seconds
This exploratory systematic review and meta-analysis pooled four randomized controlled trials of tavapadon in patients with Parkinson’s disease. The review assessed changes in Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores and treatment-related adverse events. Tavapadon improved combined MDS-UPDRS Parts II and III scores versus comparator, with a pooled mean difference of -8.80 (95% CI -13.51 to -4.09; p = 0.0003). It also increased the risk of treatment-related adverse events (RR 1.96; 95% CI 1.19 to 3.25; p = 0.0236), with substantial heterogeneity.
Key findings
- Combined MDS-UPDRS Parts II + III scores improved with tavapadon (MD -8.80; 95% CI -13.51 to -4.09; p = 0.0003).
- Part III scores improved (MD -5.44; 95% CI -8.53 to -2.35; p = 0.0006), as did Part II scores (MD -1.66; 95% CI -2.39 to -0.92; p < 0.0001).
- Treatment-related adverse events were more likely with tavapadon (RR 1.96; 95% CI 1.19 to 3.25; p = 0.0236); heterogeneity was substantial.
Why it matters
The pooled results suggest short-term improvements in both motor symptoms and functional outcomes, alongside an increased risk of treatment-related adverse events. Considering both outcomes is important when evaluating a potential therapy for Parkinson’s disease, particularly because the evidence comes from short-term trials and the adverse-event findings were heterogeneous.
What to keep in mind
The evidence is based on four randomized trials and short-term follow-up; the analysis also reports substantial heterogeneity in treatment-related adverse events.